Generex Biotechnology Corp’s (OTCMKTS: GNBT) subsidiary NuGenerex Immuno-Oncology has announced that the comp0any received a valuation of $535 million for a globally recognized, independent appraisal and...
Generex Biotechnology Corporation (OTCMKTS:GNBT) has made a tremendous step on its quest to come up with a vaccine targeting G4 EA H1N1 swine influenza. Reports show...
Generex Biotechnology Corporation (OTCMKTS:GNBT) has such a strong portfolio of immune-oncology assets, diagnostics, and medical devices. An acquisition strategy the company applies from time to time...
Generex Biotechnology Corporation’s (OTCMKTS:GNBT) wholly-owned subsidiary NuGenerex Immuno-Oncology launched a vaccine development initiative to address the emerging new pandemic threat from the recently identified Swine flu...
For the last couple of months, the world has experienced panic and disarray from the outbreak and the rapid spread of coronavirus. However, it is now...
Generex Biotechnology Corporation (OTCMKTS:GNBT) entered a pact to utilize the computational tools of EpiVax to develop a Peptide vaccine against nCOV-2019 coronavirus. EpiVax has got expertise...
Generex Biotechnology Corporation (OTCMKTS:GNBT) announced about two weeks ago that it garnered the American Podiatric Medical Association’s (APMA) ‘Seal of Approval’ for its would conforming tissue...
Generex Biotechnology Corporation (OTCMKTS:GNBT) has announced the signing of a letter of intent to merge with Kiromic Inc. to form a new Generex entity that shall...
In a new wake of events, Generex Biotechnology Corporation (OTCMKTS:GNBT) has introduced a platform, which primarily deals with in-depth patient health management services. NuGenerex Medical Marketing...
